Biogen throws itself back into muddled data arguments with more details on its antisense ALS drug

With a highly watched FDA decision deadline coming in late January, Biogen and Ionis dropped the full data on the Phase III study of their ALS drug tofersen in the New England Journal of Medicine on Wednesday. Biogen is looking for approval for tofersen in a very small subset of…

Click here to view original post